Janux Therapeutics, Inc.
JANX Healthcare Biotechnology
Janux Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $10.0 million, down 5.55% from fiscal 2024. In the quarter to June 2026, revenue grew 2,238.7%, EPS grew 36.4% and free cash flow grew 150.6%, each against the same quarter a year earlier.
Follow JANX
Janux Therapeutics, Inc. (JANX) Altman Z-score
Janux Therapeutics, Inc.'s Altman Z-score for fiscal 2025 is 11.61, in the safe zone (above 2.99).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2025 | 11.61 | (33.51) |
| FY2024 | 45.12 | 37.43 |
| FY2023 | 7.69 | 0.08 |
| FY2022 | 7.61 | (13.73) |
| FY2021 | 21.34 | — |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.95 | — | 1.14 | |
| Retained earnings / total assets | (0.35) | — | −0.49 | |
| EBIT / total assets | (0.16) | — | −0.52 | |
| Market value of equity / total liabilities | 19.11 | — | 11.47 | |
| Sales / total assets | 0.01 | — | 0.01 | |
| Altman Z-score | Safe zone | 11.61 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Safe zone | 26.48 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| JANX Janux Therapeutics, Inc. | 11.6× |
| IMTX Immatics N.V. compare | 6.8× |
| NBTX Nanobiotix S.A. - Sponsored ADR compare | 3.4× |
| SVRA Savara Inc. compare | −3.2× |
| MNKD MannKind Corporation compare | −3.6× |
| DMRA Galecto, Inc. compare | — |
| VOR Vor Biopharma Inc. compare | — |
| BCAX Bicara Therapeutics Inc. compare | — |
| REPL Replimune Group, Inc. compare | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets